The inflammation of the thyroid gland (thyroiditis) can lead to its dysfunction, affecting the whole body, and leading to a loss in the quality of life.1 Autoimmune thyroid diseases (AITD), such as Graves’ disease and Hashimoto’s thyroiditis, affect up to 5 percent of the population in Western countries, and are one of the main etiologies of hyper- and hypothyroidism.1 Enabling clinicians to differentiate these diseases from non-autoimmune thyroid dysfunction and to make well-informed treatment decisions lead to a better patient care.1,2
The measurement of autoantibodies directed against thyroid proteins is a pivotal part of the diagnostic algorithm of both Hashimoto’s thyroiditis and Graves’ disease.1,2
The most relevant thyroid autoantibodies are:
In diseases such as AITD, where patients can often present with vague symptoms, specificity is key. With EliA™ anti-TSH-R, EliA™ anti-TPO and EliA™ anti-TG tests, we offer a fully automated and specific autoantibody test panel to support the diagnosis of AITD. In a comparison with other automated thyroid tests, EliA™ thyroid tests had the highest specificity rates (EliA anti-TSH-R test: 97.7%; manufacturer 1: 92.0%, manufacturer 2: 94.0%; EliA anti-TPO test: 96.0%, manufacturer 1: 94.0%, manufacturer 2: 91.0%; EliA anti-TG: 94%, manufacturer 1: 90.5%, manufacturer 2: 94.0%).6
The antigens for EliA anti-TSH-R and EliA anti-TPO tests are produced with high purity and reproducibility in a eukaryotic expression system. This ensures a high lot-to-lot consistency with maximum accuracy and precision within and between lots.
EliA thyroid tests enable you to perform all three relevant antibody tests from one sample in one run and on the same fully automated Phadia™ Laboratory Systems. This means that you and your clinical customers can apply the same thyroid positive control for all EliA thyroid tests and share common system reagents, saving time and reducing costs.